India Grants First-Ever Approval for a Dengue Prevention Vaccine

The Drugs Controller General of India (DCGI) has granted marketing approval for a dengue prevention vaccine for the first time in the country, marking a significant milestone in India's fight against the mosquito-borne viral disease.

Detailed Summary

India has for the first time approved a vaccine specifically for the prevention of dengue fever, a viral disease transmitted by Aedes mosquitoes that causes a significant public health burden across the country, especially during monsoon and post-monsoon months. The approval by the DCGI, India's apex drug regulatory authority, paves the way for the vaccine's eventual rollout, subject to further regulatory, pricing, and distribution processes.

Historical Background

Dengue has been endemic in India for decades, with periodic large-scale outbreaks; unlike some other vaccine-preventable diseases, no dengue vaccine had previously received Indian regulatory approval, making this a historic advancement in the country's vaccine landscape.

Previous Related Events

Globally, a small number of dengue vaccines (such as Dengvaxia and Qdenga) have received approval in various countries over the past decade, though widespread rollout has been limited by concerns over vaccine efficacy varying by prior dengue exposure status.

Why Important for TNPSC

Vaccine approvals and public health milestones are commonly tested under the Health and Science & Technology sections of TNPSC General Studies papers.

Scientific Relevance

Dengue vaccines work by priming the immune system against the dengue virus's four serotypes; scientific and clinical-trial evidence on safety and efficacy across different age groups and prior-exposure statuses is central to regulatory approval.

Key Highlights

• First-ever DCGI approval for a dengue prevention vaccine in India.
• Marks a major step in India's dengue-control strategy.

Important Facts

Important Years and Dates

Approval reported on July 21, 2026.

Ministries Involved

Ministry of Health and Family Welfare, Government of India; Central Drugs Standard Control Organisation (CDSCO).

Organisations and Headquarters

CDSCO/DCGI office - New Delhi.

Related Static GK

Dengue is caused by four distinct serotypes (DENV-1 to DENV-4) transmitted by the Aedes aegypti mosquito; India's National Vector Borne Disease Control Programme (NVBDCP) coordinates dengue surveillance and control.

Important Terms and Definitions

DCGI: Drugs Controller General of India, the national regulatory authority for approving new drugs and vaccines. Serotype: A distinct variation within a species of virus, distinguished by antigenic properties.

Exam-Oriented Notes

Remember DCGI as India's central drug/vaccine approval authority - a recurring fact tested alongside vaccine-related current affairs.

Memorization Points

Regulator: DCGI; Milestone: First dengue vaccine approval in India; Date: July 21, 2026.

3 TNPSC-Style MCQs

Q1. Which authority granted India's first approval for a dengue prevention vaccine?
(a) ICMR (b) DCGI (c) WHO (d) AIIMS
Answer: (b) DCGI

Q2. Dengue fever is transmitted by which mosquito genus?
(a) Anopheles (b) Culex (c) Aedes (d) Mansonia
Answer: (c) Aedes

Q3. How many serotypes of the dengue virus exist?
(a) Two (b) Three (c) Four (d) Six
Answer: (c) Four